Old explanation still works as there are no major updates: quoting here the gist of GINA 2025 guidelines for reference:
The transition from GINA 2024 to GINA 2025 asthma guidelines reflects a clear shift toward safer, more personalized, and anti-inflammatory–focused care. While GINA 2024 had already introduced the preference for ICS–formoterol as a reliever (Track 1) over SABA, GINA 2025 strengthens this further by promoting ICS–formoterol across almost all treatment steps, significantly de-emphasizing SABA due to safety concerns. A key conceptual change is the discouragement of the term “mild asthma,” highlighting that even seemingly mild disease carries a risk of severe exacerbations or death, thereby reinforcing early and consistent use of inhaled corticosteroids. The 2025 update also places greater emphasis on objective diagnosis, even in patients already on treatment, and expands the role of biomarkers like FeNO and blood eosinophils in diagnosis, phenotyping, and guiding biologic therapy. In addition, there is a stronger push toward individualized treatment and shared decision-making, including inhaler choice based on patient preference and environmental considerations. Pediatric asthma (especially ≤5 years) now has clearer diagnostic criteria, and updates in exacerbation management aim to avoid overtreatment. Overall, GINA 2025 advances toward precision medicine, with less reliance on symptom-based labels and more focus on risk reduction, inflammation control, and tailored therapy.